Screening for Cardio-Metabolic Disease
In the Middle East since 2008

Metabolic Syndrome (MS) is a combination of medical disorders that, taken together, increase the risk of cardiovascular disease and diabetes. It affects about one in four people in the Middle East, and prevalence increases with age. The recorded high frequency of MS and its key cardiovascular risk factors (15-60%) among the Middle East population mandates the need for prevention programmes to combat obesity, diabetes, hypertension, dyslipidemia, smoking and related comorbidities. Early prevention and control is of utmost importance.

EuroMedix provides health-screening tools and implements concepts related to:

• Early prevention of common diseases (primary prevention)
• Early detection of risk factors or illness development (secondary prevention) Management of patients with installed diseases in order to improve the prognosis and outcome (tertiary prevention)


A further dimension of Cardiometabolic Health & Advanced Risk Management (CHARM) concerns new technologies that measure vascular age, arterial stiffness, AGEs (Advanced Glycation End-products) ...

Diverse EuroMedix technologies have been used to assess cardio-metabolic health in the Middle-East:

• Arterial Stiffness, Arterial Age and AGEs (Advanced Glycation End-Products) using the MOB PWA and the AGE Reader. Arterial stiffness is a consequence of age and atherosclerosis. Arterial Age suggests that there can be a substantial difference between your age and the health of your blood vessels. Increased arterial stiffness and high levels of AGE result in the elevated occurrence of cardio-metabolic events.
• Lipid profile testing using the CardioChek PA SILVER, including Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides. A simple finger prick and 2 minutes of analysis/reaction time is all that is needed.
• Glycated Hemoglobin testing using the A1CNow+ & Clover A1c: a capillary blood sample in exactly 5 minutes.